Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK1 | P57059 | 2/20 | 0.53 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.53 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.53 |
| ▸ | SYK | P43405 | 2/20 | 0.53 |
| ▸ | AXL | P30530 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 5/20 | 0.47 |
| ▸ | JAK1 | P23458 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489767 | 0.88 | AXL (0.61) | SIK1SIK2SIK3SYKAXL | |
| SCHEMBL4499210 | 0.80 | SIK1 (0.56) | SIK1SIK2SIK3AXLFLT3 | |
| SCHEMBL4491720 | 0.79 | SIK1 (0.56) | SIK1SIK2SIK3SYKAXL | |
| SCHEMBL4497460 | 0.77 | BTK (0.62) | SIK1SIK2SIK3SYKAXL | |
| SCHEMBL4504802 | 0.77 | PKMYT1 (0.62) | FLT3KCNH2MAPK9MAPK10PAK1 | |
| SCHEMBL4493690 | 0.76 | SIK1 (0.54) | SIK1SIK2SIK3SYKAXL | |
| SCHEMBL5686226 | 0.76 | BTK (0.56) | SIK1SIK2SIK3SYKAXL | |
| SCHEMBL4489927 | 0.75 | CDK4 (0.66) | SYKBRD4AURKAINSRCDK1 | |
| SCHEMBL5686229 | 0.74 | JAK2 (0.43) | SIK1SIK2SIK3AXLFLT3 | |
| SCHEMBL5686150 | 0.74 | LCK (0.49) | SYKBTKJAK1JAK3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | SIK1 1588/4885SIK2 1559/4885SIK3 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.